Gene therapy for Rett syndrome: prospects and challenges

Kamal K. E. Gadalla, Paul D. Ross, Ralph D. Hector, Noha G. Bahey, Mark E.S. Bailey, Stuart R. Cobb

Research output: Contribution to journalArticlepeer-review


Rett syndrome (RTT) is a neurological disorder that affects females and is caused by loss-of-function mutations in the X-linked gene MECP2. Deletion of Mecp2 in mice results in a constellation of neurological features that resemble those seen in RTT patients. Experiments in mice have demonstrated that restoration of MeCP2, even at adult stages, reverses several aspects of the RTT-like pathology suggesting that the disorder may be inherently treatable. This has provided an impetus to explore several therapeutic approaches targeting RTT at the level of the gene, including gene therapy, activation of MECP2 on the inactive X chromosome and read-through and repair of RTT-causing mutations. Here, we review these different strategies and the challenges of gene-based approaches in RTT.
Original languageEnglish
Pages (from-to)467-484
Number of pages18
JournalFuture Neurology
Issue number5
Publication statusPublished - 2015


Dive into the research topics of 'Gene therapy for Rett syndrome: prospects and challenges'. Together they form a unique fingerprint.

Cite this